Skip to main content
Top
Published in: Calcified Tissue International 3/2017

01-03-2017 | Original Research

Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy

Authors: Shijing Qiu, George W. Divine, Saroj Palnitkar, Pooja Kulkarni, Trent S. Guthrie, Mahalakshmi Honasoge, Sudhaker D. Rao

Published in: Calcified Tissue International | Issue 3/2017

Login to get access

Abstract

Atypical femur fracture (AFF), a serious complication of long-term bisphosphonate therapy, is usually preceded by an incomplete fracture appearing on the lateral femur. AFF is most likely the result of severely suppressed bone turnover (SSBT). However, the differences in bone structure and turnover between patients with incomplete and complete AFF remain unknown. We examined trans-iliac bone biopsies from 12 white postmenopausal women with AFF (incomplete = 5; complete = 7) on BP therapy of >5 years and 43 healthy white premenopausal women. Histomorphometric measurements were performed separately in cancellous, intracortical and endosteal envelopes. Of the 43 histomorphometric measurements on 3 difference bone surfaces (cancellous, intracortical and endosteal), only 2 bone resorption variables (Oc.S/BS and Oc.S/NOS) on the endosteal surface were significantly lower in patients with complete AFF than those with incomplete AFF. Compared to healthy premenopausal women, the trabecular bone volume, thickness and number were all significantly lower in patients with AFF. The dynamic bone formation variables in patients with AFF were significantly reduced on all bone surfaces. The likelihood of a biopsy with no tetracycline labeling was significantly higher in AFF patients than in healthy premenopausal women. Based on these results, we conclude that there are no significant differences in bone turnover between patients with incomplete and complete AFF, suggesting that the suppression of bone turnover had already existed in the femur with incomplete AFF. Compared to healthy premenopausal women, bone turnover is similarly suppressed in patients with either type of AFF.
Literature
1.
go back to reference Marcus R, Bouxsein ML (2008) Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Elsevier, Amsterdam, pp 1725–1742 Marcus R, Bouxsein ML (2008) Bisphosphonates: Pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Elsevier, Amsterdam, pp 1725–1742
2.
go back to reference Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed
3.
go back to reference McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340CrossRefPubMed McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340CrossRefPubMed
4.
go back to reference Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729–1737CrossRefPubMedPubMedCentral Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729–1737CrossRefPubMedPubMedCentral
5.
go back to reference Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMed Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMed
6.
go back to reference Kharazmi M, Michaelsson K, Hallberg P (2014) Prodromal symptoms in patients with bisphosphonate-associated atypical fractures of the femur. J Bone Miner Metab 33:516–522CrossRefPubMed Kharazmi M, Michaelsson K, Hallberg P (2014) Prodromal symptoms in patients with bisphosphonate-associated atypical fractures of the femur. J Bone Miner Metab 33:516–522CrossRefPubMed
7.
go back to reference Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29:1–23CrossRefPubMed Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29:1–23CrossRefPubMed
8.
go back to reference Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294CrossRefPubMed Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294CrossRefPubMed
9.
go back to reference Ahlman MA, Rissing MS, Gordon L (2012) Evolution of bisphosphonate related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res 27:496–498CrossRefPubMed Ahlman MA, Rissing MS, Gordon L (2012) Evolution of bisphosphonate related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res 27:496–498CrossRefPubMed
10.
go back to reference Porrino JA Jr, Kohl CA, Taljanovic M, Rogers LF (2010) Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. Am J Roentgenol 194:1061–1064CrossRef Porrino JA Jr, Kohl CA, Taljanovic M, Rogers LF (2010) Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. Am J Roentgenol 194:1061–1064CrossRef
11.
go back to reference Harborne K, Hazlehurst JM, Shanmugaratnam H, Pearson S, Doyle A, Gittoes NJ, Choudhary S, Crowley RK (2015) Compliance with established guidelines for the radiological reporting of atypical femoral fractures. Br J Radiol 89:20150443CrossRefPubMedPubMedCentral Harborne K, Hazlehurst JM, Shanmugaratnam H, Pearson S, Doyle A, Gittoes NJ, Choudhary S, Crowley RK (2015) Compliance with established guidelines for the radiological reporting of atypical femoral fractures. Br J Radiol 89:20150443CrossRefPubMedPubMedCentral
12.
go back to reference Kajino Y, Kabata T, Watanabe K, Tsuchiya H (2012) Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy. J Orthop Sci 17:313–318CrossRefPubMed Kajino Y, Kabata T, Watanabe K, Tsuchiya H (2012) Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy. J Orthop Sci 17:313–318CrossRefPubMed
13.
go back to reference Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE (2009) Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 24:1736–1740CrossRefPubMed Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE (2009) Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 24:1736–1740CrossRefPubMed
14.
go back to reference La Rocca Vieira R, Rosenberg ZS, Allison MB, Im SA, Babb J, Peck V (2012) Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. Am J Roentgenol 198:1144–1151CrossRef La Rocca Vieira R, Rosenberg ZS, Allison MB, Im SA, Babb J, Peck V (2012) Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. Am J Roentgenol 198:1144–1151CrossRef
16.
17.
go back to reference Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620CrossRefPubMed Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620CrossRefPubMed
18.
go back to reference Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531CrossRefPubMed Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531CrossRefPubMed
19.
go back to reference Iwata K, Mashiba T, Hitora T, Yamagami Y, Yamamoto T (2014) A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy. Bone 64:183–186CrossRefPubMed Iwata K, Mashiba T, Hitora T, Yamagami Y, Yamamoto T (2014) A large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy. Bone 64:183–186CrossRefPubMed
20.
go back to reference Koh JS, Goh SK, Png MA, Kwek EB, Howe TS (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24:75–81CrossRefPubMed Koh JS, Goh SK, Png MA, Kwek EB, Howe TS (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24:75–81CrossRefPubMed
21.
go back to reference Recker R, Lappe J, Davies KM, Heaney R (2004) Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628–1633CrossRefPubMed Recker R, Lappe J, Davies KM, Heaney R (2004) Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628–1633CrossRefPubMed
22.
go back to reference Recker RR, Ste-Marie LG, Chavassieux P, McClung MR, Lundy MW (2015) Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Osteoporos Int 26:327–337CrossRefPubMed Recker RR, Ste-Marie LG, Chavassieux P, McClung MR, Lundy MW (2015) Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Osteoporos Int 26:327–337CrossRefPubMed
23.
24.
go back to reference Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1996) Effect of ethnicity and age or menopause on the structure and geometry of iliac bone. J Bone Miner Res 11:1967–1975CrossRefPubMed Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1996) Effect of ethnicity and age or menopause on the structure and geometry of iliac bone. J Bone Miner Res 11:1967–1975CrossRefPubMed
25.
go back to reference Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 12:498–508CrossRefPubMed Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 12:498–508CrossRefPubMed
26.
go back to reference Min BW, Koo KH, Park YS, Oh CW, Lim SJ, Kim JW, Lee KJ, Lee YK (2016) Novel scoring system for identifying impending complete fractures in incomplete atypical femoral fractures. J Clin Endocrinol Metab. doi:10.1210/jc.2016-2787 Min BW, Koo KH, Park YS, Oh CW, Lim SJ, Kim JW, Lee KJ, Lee YK (2016) Novel scoring system for identifying impending complete fractures in incomplete atypical femoral fractures. J Clin Endocrinol Metab. doi:10.​1210/​jc.​2016-2787
27.
go back to reference Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17CrossRefPubMedPubMedCentral Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17CrossRefPubMedPubMedCentral
28.
go back to reference Hauge E, Mosekilde L, Melsen F (1999) Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 25:389–395CrossRefPubMed Hauge E, Mosekilde L, Melsen F (1999) Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 25:389–395CrossRefPubMed
29.
go back to reference Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771CrossRefPubMed Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771CrossRefPubMed
30.
go back to reference Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789CrossRefPubMed Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789CrossRefPubMed
31.
go back to reference Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737CrossRefPubMed Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737CrossRefPubMed
32.
go back to reference Tripto-Shkolnik L (2013) Atypical femoral fractures and their relation to bisphosphonate use. Isr Med Assoc J 15:447–450PubMed Tripto-Shkolnik L (2013) Atypical femoral fractures and their relation to bisphosphonate use. Isr Med Assoc J 15:447–450PubMed
33.
go back to reference Uhthoff HK, Jaworski ZF (1985) Periosteal stress-induced reactions resembling stress fractures. A radiologic and histologic study in dogs. Clin Orthop Relat Res (199):284–291 Uhthoff HK, Jaworski ZF (1985) Periosteal stress-induced reactions resembling stress fractures. A radiologic and histologic study in dogs. Clin Orthop Relat Res (199):284–291
34.
go back to reference Li J, Miller MA, Hutchins GD, Burr DB, Li J, Miller MA, Hutchins GD, Burr DB (2005) Imaging bone microdamage in vivo with positron emission tomography. Bone 37(6):819–824CrossRefPubMed Li J, Miller MA, Hutchins GD, Burr DB, Li J, Miller MA, Hutchins GD, Burr DB (2005) Imaging bone microdamage in vivo with positron emission tomography. Bone 37(6):819–824CrossRefPubMed
35.
go back to reference McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768CrossRefPubMed McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768CrossRefPubMed
36.
go back to reference Miller PD, McCarthy EF (2015) Bisphosphonate-associated atypical sub-trochanteric femur fractures: Paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 44:477–482CrossRefPubMed Miller PD, McCarthy EF (2015) Bisphosphonate-associated atypical sub-trochanteric femur fractures: Paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 44:477–482CrossRefPubMed
37.
go back to reference Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66–S80CrossRefPubMed Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66–S80CrossRefPubMed
38.
go back to reference D’Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G (2008) Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 23:373–379CrossRefPubMed D’Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G (2008) Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 23:373–379CrossRefPubMed
39.
40.
go back to reference Jobke B, Milovanovic P, Amling M, Busse B (2014) Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59:37–43CrossRefPubMed Jobke B, Milovanovic P, Amling M, Busse B (2014) Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59:37–43CrossRefPubMed
41.
go back to reference Portero-Muzy NR, Chavassieux PM, Bouxsein ML, Gineyts E, Garnero P, Chapurlat RD (2012) Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes. Bone 51:714–719CrossRefPubMed Portero-Muzy NR, Chavassieux PM, Bouxsein ML, Gineyts E, Garnero P, Chapurlat RD (2012) Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes. Bone 51:714–719CrossRefPubMed
42.
go back to reference Tamminen IS, Yli-Kyyny T, Isaksson H, Turunen MJ, Tong X, Jurvelin JS, Kroger H (2013) Incidence and bone biopsy findings of atypical femoral fractures. J Bone Miner Metab 31:585–594CrossRefPubMed Tamminen IS, Yli-Kyyny T, Isaksson H, Turunen MJ, Tong X, Jurvelin JS, Kroger H (2013) Incidence and bone biopsy findings of atypical femoral fractures. J Bone Miner Metab 31:585–594CrossRefPubMed
43.
go back to reference Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44CrossRefPubMed Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44CrossRefPubMed
44.
go back to reference Jamal SA, Dion N, Ste-Marie LG (2011) Atypical femoral fractures and bone turnover. N Engl J Med 365:1261–1262CrossRefPubMed Jamal SA, Dion N, Ste-Marie LG (2011) Atypical femoral fractures and bone turnover. N Engl J Med 365:1261–1262CrossRefPubMed
Metadata
Title
Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy
Authors
Shijing Qiu
George W. Divine
Saroj Palnitkar
Pooja Kulkarni
Trent S. Guthrie
Mahalakshmi Honasoge
Sudhaker D. Rao
Publication date
01-03-2017
Publisher
Springer US
Published in
Calcified Tissue International / Issue 3/2017
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-016-0223-6

Other articles of this Issue 3/2017

Calcified Tissue International 3/2017 Go to the issue

Letter to the Editor

Letter to the Editor

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.